Mumbai, Maharashtra, India
An ageing population and rising drug costs are underlining the increasingly critical role of cost-effective generic medicines. Simultaneously, the highly competitive generics industry is pressurising the mainstream pharmaceutical sector to develop innovative drugs.
"An ageing population, spiralling healthcare expenditures, and an immediate need for cheap, effective medicines will be the main drivers in the European generics market", notes Frost & Sullivan (http://www.healthcare.frost.com) Research Analyst Sumanth Kambhammettu in a recent study on Pricing and Reimbursement Issues for Generics and Biosimilar Markets in Europe. "Various studies have indicated the cost savings obtained from generics and several governments are now actively engaged in promoting them."
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the Pricing and Reimbursement Issues for Generics and Biosimilar Markets in Europe (B796 - 52) then send an e-mail to Shwetha Thomas , Corporate Communications, at sthomas@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
Faced with the mounting burden of rising pharmaceutical costs and a rapidly ageing population, European governments are under immense pressure to implement corrective measures. Several countries have resorted to methods such as generic substitution and reference pricing to lower pharmaceutical pricing.
In addition, some countries are offering incentives to pharmacists and physicians to prescribe generics - a trend that will have a considerable impact on the generics market. The advent of biosimilars is also projected to a key factor in pushing down drug prices.
However, disparate country-specific policies regarding generics are causing significant variations in market development. Generics manufacturers confront further hurdles such as EU accession, lack of Roche/Bolar provision and delay in marketing authorisation applications.
"Although EU accession is believed to provide long-term benefits to generics manufacturers, policy harmonisation is expected to take a few years," explains Mr. Kambhammettu. "In addition, the lack of provisions such as the Roche/Bolar provision, which allows for research to be carried out before the loss of patent exclusivity, will delay generic approvals in Europe."
To succeed in a highly competitive environment and accelerate their time-to-market, participants should leverage the potential of low-cost contract manufacturing markets such as India and China. Strategic agreements between companies operating in different countries will also yield synergistic benefits. Finally, efforts must be directed to optimising product portfolios and devising long-term R&D strategies.
Pricing and Reimbursement Issues for Generics and Biosimilar Markets in Europe is part of the Pharmaceutical & Biotechnology Subscription, which also includes research in the following markets: Pricing and Reimbursement Issues for Pharmaceuticals in Europe, World Stem Cell Therapeutics Markets and European Cancer Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
Pricing and Reimbursement Issues for Generics and Biosimilar Markets in Europe
B796 - 52
Shwetha Thomas, Corporate Communications - South Asia & Middle East, Frost & Sullivan, +91 (022) 4001 3429 sthomas@frost.com
Melina Trevino, Corporate Communications - Americas, Frost & Sullivan, +1 210 247 2440 melina.trevino@frost.com
Source: Frost & Sullivan (Business Wire India)
Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.
